搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號 規(guī)格
Recombinant Clostridium perfringens tRNA (guanine-N (1)-)-methyltransferase (trmD) CSB-YP610496CAAP
CSB-EP610496CAAP
CSB-BP610496CAAP
CSB-MP610496CAAP
CSB-EP610496CAAP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Clostridium perfringens Elongation factor Ts (tsf) CSB-YP610497CAAP
CSB-EP610497CAAP
CSB-BP610497CAAP
CSB-MP610497CAAP
CSB-EP610497CAAP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Clostridium perfringens Ribosome-binding factor A (rbfA) CSB-YP610498CAAP
CSB-EP610498CAAP
CSB-BP610498CAAP
CSB-MP610498CAAP
CSB-EP610498CAAP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Clostridium perfringens D-ribose pyranase (rbsD) CSB-YP610499CAAP
CSB-EP610499CAAP
CSB-BP610499CAAP
CSB-MP610499CAAP
CSB-EP610499CAAP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Clostridium perfringens Pyrrolidone-carboxylate peptidase (pcp) CSB-YP610500CAAP
CSB-EP610500CAAP
CSB-BP610500CAAP
CSB-MP610500CAAP
CSB-EP610500CAAP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Clostridium perfringens Trigger factor (tig) CSB-YP610501CAAP
CSB-EP610501CAAP
CSB-BP610501CAAP
CSB-MP610501CAAP
CSB-EP610501CAAP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Clostridium perfringens Thiamine-phosphate synthase (thiE) CSB-YP610502CAAP
CSB-EP610502CAAP
CSB-BP610502CAAP
CSB-MP610502CAAP
CSB-EP610502CAAP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Clostridium perfringens Enolase (eno) CSB-YP610503CAAP
CSB-EP610503CAAP
CSB-BP610503CAAP
CSB-MP610503CAAP
CSB-EP610503CAAP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Clostridium perfringens UPF0313 protein CPR_1216 (CPR_1216), partial CSB-YP610504CAAP
CSB-EP610504CAAP
CSB-BP610504CAAP
CSB-MP610504CAAP
CSB-EP610504CAAP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Clostridium perfringens DNA mismatch repair protein mutL (mutL), partial CSB-YP610505CAAP
CSB-EP610505CAAP
CSB-BP610505CAAP
CSB-MP610505CAAP
CSB-EP610505CAAP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Clostridium perfringens Cobalamin synthase (cobS), partial CSB-YP610506CAAP1
CSB-EP610506CAAP1
CSB-BP610506CAAP1
CSB-MP610506CAAP1
CSB-EP610506CAAP1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Clostridium perfringens UPF0597 protein CPR_0790 (CPR_0790) CSB-YP610507CAAP
CSB-EP610507CAAP
CSB-BP610507CAAP
CSB-MP610507CAAP
CSB-EP610507CAAP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Clostridium perfringens Phosphoribosylaminoimidazole-succinocarboxamide synthase (purC) CSB-YP610508CAAP
CSB-EP610508CAAP
CSB-BP610508CAAP
CSB-MP610508CAAP
CSB-EP610508CAAP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Clostridium perfringens Glutamine--tRNA ligase (glnS), partial CSB-YP610509CAAP
CSB-EP610509CAAP
CSB-BP610509CAAP
CSB-MP610509CAAP
CSB-EP610509CAAP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Clostridium perfringens S-adenosylmethionine decarboxylase proenzyme (speD) CSB-YP610510CAAP
CSB-EP610510CAAP
CSB-BP610510CAAP
CSB-MP610510CAAP
CSB-EP610510CAAP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Clostridium perfringens UvrABC system protein C (uvrC), partial CSB-YP610511CAAP
CSB-EP610511CAAP
CSB-BP610511CAAP
CSB-MP610511CAAP
CSB-EP610511CAAP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Clostridium perfringens Energy-coupling factor transporter ATP-binding protein EcfA 1 (ecfA1) CSB-YP610512CAAP
CSB-EP610512CAAP
CSB-BP610512CAAP
CSB-MP610512CAAP
CSB-EP610512CAAP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Clostridium perfringens Peptidase T (pepT) CSB-YP610513CAAP
CSB-EP610513CAAP
CSB-BP610513CAAP
CSB-MP610513CAAP
CSB-EP610513CAAP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Clostridium perfringens Serine--tRNA ligase (serS) CSB-YP610514CAAP
CSB-EP610514CAAP
CSB-BP610514CAAP
CSB-MP610514CAAP
CSB-EP610514CAAP-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Shigella flexneri serotype 5b Tetraacyldisaccharide 4'-kinase (lpxK) CSB-YP610515SGG
CSB-EP610515SGG
CSB-BP610515SGG
CSB-MP610515SGG
CSB-EP610515SGG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們在線留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>